Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents
| Autor: | Bennett, Charles L., Jacob, Sony *, Georgantopoulos, Peter *, Nichols, Judy *, Macdougall, Iain C * |
|---|---|
| Zdroj: | In Blood 6 December 2014 124(21):3516-3516 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|